January 1985

Enhanced Survival During Murine Gram-negative Bacterial Sepsis by Use of a Murine Monoclonal Antibody

Author Affiliations

From the Department of Surgery, University of Minnesota, Minneapolis (Drs Dunn and Cerra); and Centocor, Malvern, Pa (Dr Bogard).

Arch Surg. 1985;120(1):50-53. doi:10.1001/archsurg.1985.01390250044007

• We developed a murine monoclonal antibody (5B10 MAb) that reacted in vitro specifically to lipopolysaccharide (LPS) obtained from Escherichia coli 0111:B4. Enzyme-linked immunosorbent assay (ELISA) titers to a variety of gram-negative bacterial whole cell and LPS antigens demonstrated that this antibody may react with the O antigen portion of 0111:B4 LPS. We then examined the ability of this antibody to protect mice in vivo against a challenge of either viable bacteria or purified LPS. One milligram of 5B10 MAb was administered intraperitoneally (IP) and protected against a lethal challenge of either viable E coli 0111:B4 or 0111:B4 LPS, but no other type of bacterial or LPS challenge. Protection occurred in an antibody dose-dependent manner, and as little as 0.01 mg of 5B10 MAb enhanced survival. We concluded that IP pretreatment with a single MAb would protect against lethal sepsis or endotoxemia in this animal model and that anti-LPS specificity was a sufficient condition for an antibody to protect during bacteremia, confirming the importance of LPS in the pathogenesis of gram-negative bacterial sepsis.

(Arch Surg 1985;120:50-53)